ArticleCancer immunology, immunotherapy : CII2024

A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.

Yuxin Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.